Nuformix plc (LSE:NFX) has continued to advance its focused pharmaceutical development strategy, leveraging cocrystal technology to repurpose and reformulate proven pharmaceutical molecules for severe unmet medical needs. The development-stage biopharmaceutical company utilizes crystal engineering to improve the physical properties, dissolution rates, and therapeutic bioavailability …
Oxford BioDynamics Plc (LSE:OBD) has continued the commercial rollout of its proprietary EpiSwitch® 3D genomic biomarker platform across clinical diagnostic and oncology markets. The biotechnology company translates three-dimensional chromosome conformation changes into precision diagnostic blood tests. Unlike standard genomic sequencing that only detects fixed …
Ondine Biomedical, Inc. (LSE:OBI) has accelerated the international deployment of its proprietary photodisinfection technology to combat hospital-acquired infections and antimicrobial resistance. The Canadian-headquartered medical technology company utilizes light-activated antimicrobial agents to rapidly destroy bacteria, viruses, and fungi without generating drug resistance. Its flagship platform, …
OptiBiotix Health PLC (LSE:OPTI) has accelerated the global commercialisation of its proprietary microbiome and functional food formulations across dietary supplement, pharmaceutical, and consumer healthcare industries. The life sciences company discovers and develops scientifically validated compounds that modulate the human microbiome. The group's primary intellectual …
Oxford BioMedica plc (LSE:OXB) has completed its strategic transformation from an internal drug developer into a pure-play contract development and manufacturing organisation (CDMO) specializing in viral vectors. The biotechnology leader designs and manufactures lentiviral, adeno-associated virus (AAV), and adenoviral vectors for global cell and …
Probiotix Health Plc (LSE:PBX) has achieved a decisive operational and financial inflection point, transitioning into statutory EBITDA profitability while accelerating commercial partnership revenues across international healthcare markets. The life sciences company discovers and commercialises patented probiotic formulations. The company's lead commercial asset, Lactobacillus plantarum …
Poolbeg Pharma plc (LSE:POLB) has maintained active clinical development momentum across its diversified portfolio of therapeutic candidates targeting severe hyperinflammation, cancer immunotherapy complications, and infectious diseases. The clinical-stage biopharmaceutical company utilizes a capital-light, fast-track development model. By leveraging human challenge trial data and artificial …
hVIVO plc (LSE:HVO) has solidified its global market leadership in human challenge clinical trials, completing the operational expansion and commercial ramp-up of its state-of-the-art quarantine trial facility in Canary Wharf, London. Quoted on the AIM market of the London Stock Exchange, the specialist contract …
Cambridge Nutritional Sciences PLC (LSE:CNSL) has accelerated its strategic repositioning to capture growing international demand for personalised health, nutrition, and food intolerance diagnostics. The company—formerly known as Omega Diagnostics Group PLC—has finalised its operational transition from a diversified point-of-care medical testing group into a …
Coiled Therapeutics PLC (LSE:COIL) has advanced its focused biopharmaceutical development operations, concentrating scientific resources on early-stage target validation and preclinical candidate nomination across high-unmet-need therapeutic indications. The development-stage life sciences company investigates novel biological pathways and molecular targets implicated in chronic inflammatory, fibrotic, and …